Reporting on circulating tumor DNA monitoring in metastatic cancer—From clinical validity to clinical utility-Reference-Cited by-同舟云学术

Reporting on circulating tumor DNA monitoring in metastatic cancer—From clinical validity to clinical utility

Published:2022-03-18 Issue:11 Volume:128 Page:2052-2057
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Brenner Thomsen Caroline¹²^ORCID,Dandanell Juul Amanda³,Lefèvre Anna Cecilie⁴⁵,Glismand Truelsen Christina⁴⁵,Dizdarevic Edina¹²,Ryssel Heidi⁶,Mathilde Kjær Ina²⁷,Lycke Wind Karen⁴⁵,Callesen Louise Bach⁴⁵,Faaborg Larsen Louise²,Støchkel Frank Malene⁸⁹,Fredslund Andersen Rikke¹,Garm Spindler Karen‐Lise⁴⁵,Jakobsen Anders¹²

Affiliation:

1. Danish Colorectal Cancer Center South Vejle HospitalUniversity Hospital of Southern Denmark Vejle Denmark

2. Department of Oncology Vejle HospitalUniversity Hospital of Southern Denmark Vejle Denmark

3. Odense Respiratory Research Unit Odense University Hospital Odense Denmark

4. Experimental Clinical Oncology Department of Oncology Arhus University Hospital Aarhus Denmark

5. Department of Clinical Medicine Aarhus University Hospital Aarhus Denmark

6. Department of Clinical Physiology PET and Nuclear Medicine, Rigshospitalet Copenhagen Denmark

7. Department of Biochemistry and Immunology Vejle HospitalUniversity Hospital of Southern Denmark Vejle Denmark

8. Department of Clinical Oncology and Palliative Care Zealand University Hospital Roskilde Denmark

9. Department of Clinical Medicine Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

Funder

Kræftens Bekæmpelse

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.34168

Reference43 articles.

1. How to use liquid biopsies to treat patients with cancer

2. Liquid Biopsies, What We Do Not Know (Yet)

3. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review

4. Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health

5. Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Levels of circulating tumor DNA correlate with tumor volume in gastro‐intestinal stromal tumors: an exploratory long‐term follow‐up study;Molecular Oncology;2024-05-24

2. Identification of circulating tumor DNA as a biomarker for diagnosis and response to therapies in cancer patients;International Review of Cell and Molecular Biology;2024

3. Imaging and Biomarker Surveillance for Head and Neck Squamous cell carcinoma: A Systematic Review and Appropriate Use Criteria Document;International Journal of Radiation Oncology*Biology*Physics;2023-12

4. Prognostic impact of early ctDNA dynamics during chemotherapy of metastatic cancer;Future Oncology;2023-11-15

5. ctDNA-Response evaluation criteria in solid tumors – a new measure in medical oncology;European Journal of Cancer;2023-02